Skip to main content
. 2021 Oct 29;18:212. doi: 10.1186/s12985-021-01682-1

Table 2.

Clinical characteristics of HBoV-positive and HBoV-negative patients

Variable HBoV-positive (n = 88) HBoV-negative (n = 790) X2/Z P
Gender 1.796 0.180
 Male 57 (64.8%) 453 (57.3%)
 Female 31 (35.2%) 337 (42.7%)
Age 6.059 0.048*
 < 2 56 (63.6%) 406 (51.4%)
 2–5 26 (29.5%) 271 (34.3%)
 ≧ 5 6 (6.8%) 113 (14.3%)
Clinical features
 Cough 85 (96.6%) 759 (96.1%) 0.056 1.000
 Wheezing 25 (28.4%) 140 (17.7%) 5.926 0.015*
 Tachypnea 15 (17.0%) 71 (9.0%) 5.819 0.016*
 Pharyngeal hyperaemia 65 (73.9%) 613 (77.6%) 0.627 0.429
 Rales 30 (34.1%) 214 (27.1%) 1.935 0.164
 Fever 58 (65.9%) 506 (64.1%) 0.119 0.730
 WBC, 109/L 9.2 (6.9, 11.5) 8.5 (6.8, 10.8) − 1.302 0.193
 HGB, g/L 128.0 (116.0, 137.0) 127.0 (118.0, 137.0) − 0.012 0.990
 LDH, U/L 306.5 (271.8, 344.3) 291.0 (254.5, 335.0) − 2.231 0.026*
 AST, U/L 34.6 (28.0, 39.0) 32.2 (25.6, 39.1) − 1.384 0.178
 ALT, U/L 13.9 (9.9, 20.1) 14.1 (10.1, 21.9) − 0.558 0.577
Hospitalization days 7.0 (5.0, 8.8) 6.0 (5.0, 8.0) − 0.770 0.441
Severe pneumonia 10 (11.4%) 39 (4.9%) 6.207 0.023*

Measurement data were expressed as median (IQR), and data were compared by rank sum test; Categorical variables were expressed as number and percentage, proportion were compared by chi-squared

Fever: T ≧ 37.5℃ (axillary temperature)

Reference levels: WBC (4.4–11.9)109/L, HGB (112–149) g/L, LDH (120–250) U/L, AST (13–35) U/L, ALT (7–40) U/L

*Age, Wheezing, Tachypnea, LDH and Severe pneumonia were statistically significant between the two groups (P < 0.05)